A retrospective single-center study in relapsed or refractory AML after venetoclax failure found minimal benefit from clofarabine combined with intermediate-dose cytarabine, with high early mortality. The analysis suggests limited clinical activity in this post-venetoclax setting and raises questions about where the regimen fits in sequencing strategies. For treatment landscape planning, the data are most relevant to patients and clinicians considering salvage regimens after venetoclax—an area where outcomes remain difficult and trial participation decisions are highly time-sensitive. Industry watchers will likely focus next on prospective studies or alternative combinations targeting resistance mechanisms emerging after venetoclax exposure.